We are committed to the safety of our medicines in all cases, and maintain an active pharmacovigilance programme to help ensure this.
Through our robust commitment to pharmacovigilance, we ensure we remain focused on patients' safety. Our Pharmacovigilance Department manages a pharmacovigilance system for the collection, collation, and evaluation of adverse events and the implementation of effective corrective and preventive actions.
For medical information enquiries, complaints and adverse events reporting, contact: firstname.lastname@example.org
In Canada, you can also contact: Canada_DrugSafety@hikma.com
In the EU, you can also contact: email@example.com or call +351 939 610 004
In France, you can also contact: firstname.lastname@example.org
In Germany, you can also contact: email@example.com
Code of Conduct
Last reviewed on 30 May 2022